Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML

被引：0
|
作者：
K Takahashi
E Jabbour
X Wang
R Luthra
C Bueso-Ramos
K Patel
S Pierce
H Yang
Y Wei
N Daver
S Faderl
F Ravandi
Z Estrov
J Cortes
H Kantarjian
G Garcia-Manero
机构：
[1] The University of Texas MD Anderson Cancer Center,Division of Cancer Medicine
[2] Graduate School of Medicine,Department of Hematology and Oncology
[3] Kyoto University,Department of Leukemia
[4] The University of Texas MD Anderson Cancer Center,Department of Biostatistics
[5] The University of Texas MD Anderson Cancer Center,Department of Hematopathology
[6] The University of Texas MD Anderson Cancer Center,undefined
来源：
Leukemia | 2013年 / 27卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2081 / 2083
页数：2
相关论文
共 36 条
  • [1] Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML
    Takahashi, K.
    Jabbour, E.
    Wang, X.
    Luthra, R.
    Bueso-Ramos, C.
    Patel, K.
    Pierce, S.
    Yang, H.
    Wei, Y.
    Daver, N.
    Faderl, S.
    Ravandi, F.
    Estrov, Z.
    Cortes, J.
    Kantarjian, H.
    Garcia-Manero, G.
    LEUKEMIA, 2013, 27 (10) : 2081 - 2083
  • [2] Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia
    Meggendorfer, Manja
    de Albuquerque, Andreia
    Nadarajah, Niroshan
    Alpermann, Tamara
    Kern, Wolfgang
    Steuer, Kimberly
    Perglerova, Karolna
    Haferlach, Claudia
    Schnittger, Susanne
    Haferlach, Torsten
    HAEMATOLOGICA, 2015, 100 (12) : E487 - E490
  • [3] Temporal Acquisition of FLT3-ITD or RAS Mutation at Transformation to AML from MDS: Clinical Implications
    Badar, Talha
    Thompson, Philip A.
    George, Binsah
    Daver, Naval
    Borthakur, Gautam
    Cortes, Jorge E.
    Konopleva, Marina
    Kadia, Tapan M.
    Bohannan, Zach
    Pierce, Sherry
    Jabbour, Elias
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Patel, Keyur P.
    Luthra, Raja
    Sukholutsky, Victoria
    Manero, Guillermo Garcia
    BLOOD, 2014, 124 (21)
  • [4] FLT3 Inhibitor Therapy for Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Impact On Survival According to FLT3 Status.
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Gautam, Borthakur
    Parikh, Sameer A.
    Konopleva, Marina
    Kornblau, Steven M.
    Andreeff, Michael
    O'Brien, Susan
    Cones, Jorge
    BLOOD, 2009, 114 (22) : 424 - 425
  • [5] Internal tandem duplication of FLT3 and activating mutation of D835 analyses in AML and MDS patients
    Lo Nigro, C
    Mattei, D
    Mordini, N
    Cusano, R
    Seri, M
    Gallamini, A
    7TH ANNUAL MEETING OF THE EUROPEAN HAEMATOLOGY ASSOCIATION, 2002, : 179 - 184
  • [6] FLT3 internal tandem duplication and FLT3-D835 mutation in 80 AML patients categorized into cytogenetic risk groups
    Maly, Ewa
    Przyborska, Marta
    Nowak, Tomasz
    Nowak, Jerzy
    Januszkiewicz, Danuta
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2010, 64 : 466 - 470
  • [7] Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis
    Takahashi, Koichi
    Jabbour, Elias J.
    Wang, Xuemei
    Ghanem, Hady
    Pemmaraju, Naveen
    Ravandi, Farhad
    Cortes, Jorge E.
    Faderl, Stefan
    Kadia, Tapan M.
    Borthakur, Gautam
    Wierda, William G.
    Pierce, Sherry A.
    Estrov, Zeev
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2012, 120 (21)
  • [8] the acquisition of cytogenetic abnormalities or mutations of FLT3 or RAS in patients with lowrisk myelodysplastic syndrome predictive of myeloblastic acute leukemia transformation?
    Eclache, Virginie
    HEMATOLOGIE, 2013, 19 (06): : 360 - 361
  • [9] Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome
    Huls, Gerwin
    Chitu, Dana A.
    Tick, Lidwine
    Boersma, Rinske
    Breems, Dimitri
    Herbers, Alexandra
    Klein, Saskia K.
    de Jonge, Suzan
    Westerweel, Peter E.
    Cruijsen, Marjan
    Hoogendoorn, Mels
    Cuijpers, Marlous
    Deeren, Dries
    Bailly, Benjamin
    Visser, Otto
    van Rhenen, Anna
    Posthuma, Eduard F. M.
    Valk, Peter J. M.
    Cloos, Jacqueline
    Ammatuna, Emanuele
    Refos, Jeannine M.
    Fakkert, R.
    Lowenberg, Bob
    Ossenkoppele, Gert J.
    ANNALS OF HEMATOLOGY, 2025, 104 (01) : 361 - 368
  • [10] A Phase II Expansion Study Of Vorinostat In Combination With Idarubicin and Cytarabine For Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations
    Takahashi, Koichi
    Jabbour, Elias
    Ravandi, Farhad
    Borthakur, Gautam
    Cortes, Jorge E.
    Kadia, Tapan
    O'Brien, Susan
    Thomas, Deborah A.
    Faderl, Stefan
    Bass, Joyce
    Wierda, William G.
    Daver, Naval
    DiNardo, Courtney D.
    Pierce, Sherry
    Brandt, Mark
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2013, 122 (21)
1234